Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Master Rollover Protocol for Continued Safety Assessment of Study Drug

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02632994
Expanded Access Status : Available
First Posted : December 17, 2015
Last Update Posted : December 5, 2018
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Condition or disease Intervention/treatment
Cancer Drug: LY2503029

Layout table for study information
Study Type : Expanded Access
Official Title: Master Rollover Protocol for Continued Safety Assessment of Study Drug

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: LY2503029
    Administered orally.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • To be eligible patients must be currently receiving benefit in a Lilly study that has met its endpoints or has otherwise stopped.

Exclusion Criteria:

  • Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02632994


Contacts
Layout table for location contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559

Locations
Layout table for location information
United States, Tennessee
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or    317-615-4559      
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST) Eli Lilly and Company

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT02632994     History of Changes
Other Study ID Numbers: 16161
I8I-MC-JYAA ( Other Identifier: Eli Lilly and Company )
First Posted: December 17, 2015    Key Record Dates
Last Update Posted: December 5, 2018
Last Verified: December 1, 2018